23 results on '"Trisolini E"'
Search Results
2. P.05.29 DIAGNOSIS OF PLEURAL MALIGNANT MESOTHELIOMA BY EUS-GUIDED FNB
- Author
-
Armellini, E., primary, Ballarè, M., additional, Genco, C., additional, Donato, G., additional, Mazza, F., additional, Orsello, M., additional, Saettone, S., additional, Stradella, D., additional, Trisolini, E., additional, Boldorini, R., additional, and Occhipinti, P., additional
- Published
- 2019
- Full Text
- View/download PDF
3. Expression analysis and prognostic/predictive significance of a panel of microRNAs (miR-124a, miR-381, miR-637) in primary IDH-wildtype glioblastoma
- Author
-
Bertero, L, Mancuso, G, Callipo, F, Traballi, L, Cassoni, P, Senetta, R, Ruda, R, Antona, J, Trisolini, E, and Boldorini, R
- Published
- 2017
4. Lipid-induced ASK1 activation in hepatocytes and Kupffer cells mediates the increased vulnerability of fatty liver to Ischemia/Reperfusion injury in mice
- Author
-
Imarisio, C., primary, Alchera, E., additional, Revanna, C.B., additional, Valente, G., additional, Follenzi, A., additional, Trisolini, E., additional, Boldorini, R., additional, and Carini, R., additional
- Published
- 2018
- Full Text
- View/download PDF
5. P03.01 Expression analysis and prognostic/predictive significance of a panel of microRNAs (miR-124a, miR-381, miR-637) in primary IDH-wildtype glioblastoma
- Author
-
Roberta Rudà, Traballi L, Antona J, Giuseppe Mancuso, Luca Bertero, Trisolini E, Rebecca Senetta, Callipo F, Boldorini R, and Paola Cassoni
- Subjects
Cancer Research ,business.industry ,Wild type ,Biology ,medicine.disease ,Text mining ,Oncology ,Expression analysis ,microRNA ,medicine ,Cancer research ,Neurology (clinical) ,business ,POSTER PRESENTATIONS ,Mir 124a ,Glioblastoma - Abstract
Background: MicroRNAs (miRNAs) are small non-coding RNA molecules regulating mRNAs translation. Significant differences in miRNAs expression have been found in glioblastoma compared to normal brain tissue. MiR-124a, miR-381 and miR-637 are involved in regulation of pathways which are commonly deregulated in glioblastoma (MAPK/ERK, WNT/β-catenin and AKT pathways, respectively). AIM: To investigate the expression profile and prognostic/predictive role of miR-124a, miR-381 and miR-637 in primary IDH-wildtype glioblastoma. Materials and Methods: Inclusion criteria were: pathological diagnosis of primary IDH-wildtype glioblastoma (according to WHO 2016 criteria), partial/total surgical resection followed by at least one line of postoperative adjuvant treatment, ≥ 6-months follow-up after diagnosis, Caucasian ethnicity. Histological revision was performed independently by two pathologists to confirm diagnosis. IDH1/IDH2 status was assessed by Sanger sequencing according to standard protocols. Total RNA was extracted using miRNeasy FFPE (QIAGEN), miRNAs were amplified with TaqMan MicroRNA Assays (ThermoFisher) and RNU6B was used as endogenous control, while ten normal brain areas were selected as external controls. Relative quantification miRNA expression values (RQ) were calculated using the ΔΔCt method. X-tile plots and Stata (StataCorp LP) were used to calculate RQ cut-off values and for statistical analyses, respectively. Informed consent was obtained according to local regulations. Results: Here we present preliminary results based on 49 patients, 30 males (61%). Median age was 59 years (range 38–75), median KPS before surgery 80 (range 70–90). Partial resection was achieved in 27/49 (55%), total in 22/49 (45%). Median progression-free survival (PFS) was 9.4 months (range 3.5–26), median overall survival (OS) 16 months (range 3.5–42.7). Total resection and adjuvant treatment according to Stupp regimen were both associated with a better outcome as expected. Glioblastoma samples showed a reduced expression of all three miRNAs compared to normal brain. Significantly better PFS (9.9 vs 6.0 months, p=0.002) was found in patients with up-regulated miR-637 (RQ cut-off: 0.248), whereas OS difference was not significant (16.9 vs 15.6, p=0.161). A specific RQ range of miR-381 (RQ 0.104–0.287) was associated with better PFS (9.8 vs 7.4, p=0.0183), but not with OS (16.4 vs 15.8, p=0.782). No significant associations were found between miR-124a and outcome. Conclusions: A better PFS was significantly associated with miR-637 up-regulation, a finding consistent with its reported inhibitory effect on the AKT pathway. Interestingly, the favorable role of miR-381 seems to be limited to a specific range of RQ comprising the cut-off value. These preliminary findings need to be assessed in a larger series and the study is ongoing.
- Published
- 2017
6. P03.01 Expression analysis and prognostic/predictive significance of a panel of microRNAs (miR-124a, miR-381, miR-637) in primary IDH-wildtype glioblastoma
- Author
-
Bertero, L., primary, Mancuso, G., additional, Callipo, F., additional, Traballi, L., additional, Cassoni, P., additional, Senetta, R., additional, Rudà, R., additional, Antona, J., additional, Trisolini, E., additional, and Boldorini, R., additional
- Published
- 2017
- Full Text
- View/download PDF
7. Abstract P6-05-04: Stratification of breast carcinomas with double-equivocal HER2 status
- Author
-
Marchio, C, primary, Trisolini, E, additional, Maletta, F, additional, Annaratone, L, additional, Scalzo, MS, additional, Mascali, D, additional, Verdun di Cantogno, L, additional, Medico, E, additional, and Sapino, A, additional
- Published
- 2016
- Full Text
- View/download PDF
8. THU-444 - Lipid-induced ASK1 activation in hepatocytes and Kupffer cells mediates the increased vulnerability of fatty liver to Ischemia/Reperfusion injury in mice
- Author
-
Imarisio, C., Alchera, E., Revanna, C.B., Valente, G., Follenzi, A., Trisolini, E., Boldorini, R., and Carini, R.
- Published
- 2018
- Full Text
- View/download PDF
9. FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas
- Author
-
Jean-Yves Delattre, Marc Sanson, Anna Luisa Di Stefano, Marc Polivka, Elena Trisolini, Khê Hoang-Xuan, Giulia Berzero, Karima Mokhtari, Julien Savatovsky, Alberto Picca, Sheida Meunier, Yohann Schmitt, Mehdi Touat, Ahmed Idbaih, Franck Bielle, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), University of Pavia, Fondation Ophtalmologique Adolphe de Rothschild [Paris], Service de neurologie 2 [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Laboratoire de Neuropathologie Raymond Escourolle, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Lariboisière, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Foch [Suresnes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Université Pierre et Marie Curie - Paris 6 (UPMC), Service de pathologie, Hôpital Lariboisière-Fernand-Widal [APHP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Picca, A., Berzero, G., Bielle, F., Touat, M., Savatovsky, J., Polivka, M., Trisolini, E., Meunier, S., Schmitt, Y., Idbaih, A., Hoang-Xuan, K., Delattre, J. -Y., Mokhtari, K., Di Stefano, A. L., Sanson, M., Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], AP-HP Hôpital Lariboisière [Paris], and Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Oncology ,medicine.medical_specialty ,IDH1 ,business.industry ,EGFR Amplification ,Fibroblast growth factor receptor 1 ,[SDV]Life Sciences [q-bio] ,Retrospective cohort study ,Disease ,03 medical and health sciences ,0302 clinical medicine ,CDKN2A ,030220 oncology & carcinogenesis ,Internal medicine ,DNA methylation ,Medicine ,Neurology (clinical) ,Young adult ,business ,030217 neurology & neurosurgery - Abstract
ObjectiveTo characterize the prevalence and prognostic significance of major driver molecular alterations in adult midline diffuse gliomas (MLG).MethodsAdults with histologically proven MLG diagnosed between 1996 and 2017 were identified from our tumor bank, systematically reviewed, and reclassified according to WHO 2016. Targeted sequencing was performed, including determination ofH3F3A,HIST1H3B,TERTp,IDH1/2,FGFR1,p16/CDKN2A, andEGFRstatus.ResultsA total of 116 adult patients (M/F 71/45, median age 46.5 years) with MLG (17 cerebellar, 8 spinal, 30 brainstem, 57 thalamic, and 4 diencephalic nonthalamic) were identified. Most patients had high-grade disease at presentation (grade II: 11%, grade III: 15%, grade IV: 75%). Median overall survival was 17.3 months (14.5–23.8 months). Main molecular alterations observed wereTERTpromoter,H3F3A, and hotspotFGFR1(N546 and K656) mutations, in 37%, 34%, and 18% of patients, respectively.IDH1mutations only affected brainstem gliomas (6/24 vs 0/78;p= 7.5 × 10−5), were mostly non-R132H (contrasting with hemispheric gliomas,p= 0.0001), and were associated with longer survival (54 vs 12 months).TERTpromoter mutation (9.1 vs 24.2 months),CDKN2Adeletion (9.9 vs 23.8 months), and EGFR amplification (4.3 vs 23.8 months) were associated with shorter survival. Of interest, in contrast with pediatric MLG, H3K27M mutations were not associated with worse prognosis (23 vs 15 months).ConclusionsPatients with adult MLG present with unique clinical and molecular characteristics, differing from their pediatric counterparts. The identification of potentially actionableFGFR1mutations in a subset of adult MLG highlights the importance of comprehensive genomic analysis in this rare affection.
- Published
- 2018
10. Human cytomegalovirus infection triggers a paracrine senescence loop in renal epithelial cells.
- Author
-
Raviola S, Griffante G, Iannucci A, Chandel S, Lo Cigno I, Lacarbonara D, Caneparo V, Pasquero S, Favero F, Corà D, Trisolini E, Boldorini R, Cantaluppi V, Landolfo S, Gariglio M, and De Andrea M
- Subjects
- Humans, Cytomegalovirus genetics, Epithelial Cells pathology, DNA, Interleukin-6 genetics, Cytomegalovirus Infections genetics, Cytomegalovirus Infections pathology
- Abstract
Human cytomegalovirus (HCMV) is an opportunistic pathogen causing severe diseases in immunosuppressed individuals. To replicate its double-stranded DNA genome, HCMV induces profound changes in cellular homeostasis that may resemble senescence. However, it remains to be determined whether HCMV-induced senescence contributes to organ-specific pathogenesis. Here, we show a direct cytopathic effect of HCMV on primary renal proximal tubular epithelial cells (RPTECs), a natural setting of HCMV disease. We find that RPTECs are fully permissive for HCMV replication, which endows them with an inflammatory gene signature resembling the senescence-associated secretory phenotype (SASP), as confirmed by the presence of the recently established SenMayo gene set, which is not observed in retina-derived epithelial (ARPE-19) cells. Although HCMV-induced senescence is not cell-type specific, as it can be observed in both RPTECs and human fibroblasts (HFFs), only infected RPTECs show downregulation of LAMINB1 and KI67 mRNAs, and enhanced secretion of IL-6 and IL-8, which are well-established hallmarks of senescence. Finally, HCMV-infected RPTECs have the ability to trigger a senescence/inflammatory loop in an IL-6-dependent manner, leading to the development of a similar senescence/inflammatory phenotype in neighboring uninfected cells. Overall, our findings raise the intriguing possibility that this unique inflammatory loop contributes to HCMV-related pathogenesis in the kidney., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
11. Liquid Biopsy Detecting Circulating Tumor Cells in Patients with Non-Small Cell Lung Cancer: Preliminary Results of a Pilot Study.
- Author
-
Mastromarino MG, Parini S, Azzolina D, Habib S, De Marni ML, Luise C, Restelli S, Baietto G, Trisolini E, Massera F, Papalia E, Bora G, Carbone R, Casadio C, Boldorini R, and Rena O
- Abstract
Lung cancer is still the leading cause of cancer-related death worldwide. Interest is growing towards early detection and advances in liquid biopsy to isolate circulating tumor cells (CTCs). This pilot study aimed to detect epithelial CTCs in the peripheral blood of early-stage non-small cell lung cancer (NSCLC) patients. We used Smart BioSurface
® (SBS) slide, a nanoparticle-coated slide able to immobilize viable nucleated cellular fraction without pre-selection and preserve cell integrity. Forty patients undergoing lung resection for NSCLC were included; they were divided into two groups according to CTC value, with a cut-off of three CTCs/mL. All patients were positive for CTCs. The mean CTC value was 4.7(± 5.8 S.D.) per ml/blood. In one patient, next generation sequencing (NGS) analysis of CTCs revealed v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation, which has also been identified in tissue biopsy. CTCs count affected neither overall survival (OS, p = 0.74) nor progression-free survival ( p = 0.829). Multivariable analysis confirmed age ( p = 0.020) and pNodal-stage ( p = 0.028) as negative predictors of OS. Preliminary results of this pilot study suggest the capability of this method in detecting CTCs in all early-stage NSCLC patients. NGS on single cell, identified as CTC by immunofluorescence staining, is a powerful tool for investigating the molecular landscape of cancer, with the aim of personalized therapies.- Published
- 2023
- Full Text
- View/download PDF
12. Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.
- Author
-
Ebrahimi A, Korshunov A, Reifenberger G, Capper D, Felsberg J, Trisolini E, Pollo B, Calatozzolo C, Prinz M, Staszewski O, Schweizer L, Schittenhelm J, Harter PN, Paulus W, Thomas C, Kohlhof-Meinecke P, Seiz-Rosenhagen M, Milde T, Casalini BM, Suwala A, Wefers AK, Reinhardt A, Sievers P, Kramm CM, Etminam N, Unterberg A, Wick W, Herold-Mende C, Sturm D, Pfister SM, Sill M, Jones DTW, Schrimpf D, Reuss DE, Aldape K, Abdullaev Z, Sahm F, von Deimling A, and Stichel D
- Subjects
- Astrocytoma mortality, Astrocytoma pathology, Brain Neoplasms mortality, Brain Neoplasms pathology, DNA Methylation, Humans, Mutation, Prognosis, Survival Rate, Astrocytoma genetics, Brain Neoplasms genetics, Telomerase genetics
- Abstract
Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade 3. Distinction from glioblastoma variants and lower grade glial and glioneuronal tumors is a common diagnostic challenge. We compared a morphologically defined set of PXA (histPXA) with an independent set, defined by DNA methylation analysis (mcPXA). HistPXA encompassed 144 tumors all subjected to DNA methylation array analysis. Sixty-two histPXA matched to the methylation class mcPXA. These were combined with the cases that showed the mcPXA signature but had received a histopathological diagnosis other than PXA. This cohort constituted a set of 220 mcPXA. Molecular and clinical parameters were analyzed in these groups. Morphological parameters were analyzed in a subset of tumors with FFPE tissue available. HistPXA revealed considerable heterogeneity in regard to methylation classes, with methylation classes glioblastoma and ganglioglioma being the most frequent mismatches. Similarly, the mcPXA cohort contained tumors of diverse histological diagnoses, with glioblastoma constituting the most frequent mismatch. Subsequent analyses demonstrated the presence of canonical pTERT mutations to be associated with unfavorable prognosis among mcPXA. Based on these data, we consider the tumor type PXA to be histologically more varied than previously assumed. Histological approach to diagnosis will predominantly identify cases with the established archetypical morphology. DNA methylation analysis includes additional tumors in the tumor class PXA that share similar DNA methylation profile but lack the typical morphology of a PXA. DNA methylation analysis also assist in separating other tumor types with morphologic overlap to PXA. Our data suggest the presence of canonical pTERT mutations as a robust indicator for poor prognosis in methylation class PXA., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
13. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status.
- Author
-
Rrapaj E, Giacometti L, Spina P, Salvo M, Baselli GA, Veggiani C, Rena O, Trisolini E, and Boldorini RL
- Subjects
- Adult, Aged, Aged, 80 and over, B7-H1 Antigen genetics, Biomarkers metabolism, Cohort Studies, Female, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Italy, Male, Mesothelioma, Malignant metabolism, Mesothelioma, Malignant pathology, Middle Aged, Pleural Neoplasms metabolism, Pleural Neoplasms pathology, Prognosis, Retrospective Studies, B7-H1 Antigen metabolism, Mesothelioma, Malignant diagnosis, Pleural Neoplasms diagnosis
- Abstract
Malignant pleural mesothelioma (MPM) is often associated with a poor prognosis and options for the treatment of this disease are few. To date, the important role of the immune microenvironment in modifying the disease natural history is well established. The programmed cell death pathway (PD-1/PD-L1) limits the T lymphocyte activation in peripheral tissues when an inflammatory response occurs, and controls the tumour immune escape. PD-L1 is broadly expressed in several malignant tumours and associated with poor clinical outcomes. Thus, the aim of our study is to investigate the potential role of PD-L1 expression in MPM prognosis. Biopsy samples from 198 patients diagnosed with MPM were examined by immunohistochemistry (IHC) and reverse transcription-polymerase chain reaction (RT-PCR) to evaluate PD-L1 protein and gene expression. For PD-L1 protein expression we consider at least 5% membranous staining as positive. Gene expression levels were calculated with ΔΔCt method. Positive expression of PD-L1 by IHC was correlated with worse overall survival (OS; p=0.0225) in MPM patients. PD-L1 positive status was correlated with worse OS in the subgroup of patients with ECOG score <2 (p=0.0004, n=129) and these data were confirmed by multivariate analysis. No significant correlation was found between PD-L1 gene expression and OS. Our results show that PD-L1 evaluated by IHC assay may be a prognostic biomarker for MPM patients with good performance status., (Copyright © 2020 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
14. Actionable FGFR1 and BRAF mutations in adult circumscribed gliomas.
- Author
-
Trisolini E, Wardighi DE, Giry M, Bernardi P, Boldorini RL, Mokhtari K, and Sanson M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Astrocytoma genetics, Ependymoma genetics, Female, Ganglioglioma genetics, Humans, Male, Middle Aged, Mutation, Neoplasms, Neuroepithelial genetics, Retrospective Studies, Young Adult, Brain Neoplasms genetics, Glioma genetics, Proto-Oncogene Proteins B-raf genetics, Receptor, Fibroblast Growth Factor, Type 1 genetics
- Abstract
Purpose: Circumscribed gliomas -pilocytic astrocytomas (PA), gangliogliomas (GG), ependymomas (EP)- are mostly low-grade tumours but may progress to anaplasia and sometimes surgery can be challenging due to deep anatomical localization. Because of the high frequency of MAPK-pathway alterations and availability of targeted therapies for FGFR1 and BRAF-mutated tumors, we investigated these mutational hotspots in a cohort of adult circumscribed gliomas., Methods: Adult patients (>15 years) with diagnosis of PA, GG, EP and DNET were retrospectively identified from two institutions databases. Genomic DNA was extracted from formalin-fixed paraffin-embedded or frozen samples and exons including codons 546 and 656 of FGFR1 and V600 of BRAF were sequenced., Results: FGFR1 mutations were identified in 15/108 PA and were particularly frequent in optic pathway (6/9 vs. 9/108; p = 10
-4 ). FGFR1 was mutated in 3/75 grade II versus 2/7 grade III GG (p = 0.05), 1/7 DNET, 1/100 EP grade II. We found 3/108 PA with BRAF pVal600Glu and 6/108 with p.Thr599_Val600insThr. The p.Val600Glu was found in 14/75 grade II GG. No EP were BRAF mutated., Conclusions: We report actionable targets, including frequent FGFR1 mutation in optic-pathway PA that makes them excellent candidates to anti-FGFR therapies, and BRAF non-canonical mutations in PA.- Published
- 2019
- Full Text
- View/download PDF
15. Histologic retrieval rate of a newly designed side-bevelled 20G needle for EUS-guided tissue acquisition of solid pancreatic lesions.
- Author
-
Armellini E, Manfrin E, Trisolini E, Andorno S, Ballarè M, Bernardoni L, Boldorini RL, Gabbrielli A, Frulloni L, Larghi A, Occhipinti P, Scarpa A, and Crinò SF
- Subjects
- Aged, Endosonography, Female, Humans, Immunohistochemistry, Male, Middle Aged, Pancreatic Diseases diagnosis, Pancreatic Neoplasms diagnosis, Sensitivity and Specificity, Endoscopic Ultrasound-Guided Fine Needle Aspiration instrumentation, Endoscopic Ultrasound-Guided Fine Needle Aspiration methods, Endoscopic Ultrasound-Guided Fine Needle Aspiration standards, Pancreas pathology
- Abstract
Background: Innovative approaches to improve diagnostic yield of endoscopic ultrasound-guided tissue acquisition (EUS-TA) have focused on needle design with development of fine-needle biopsy (FNB) needles with microcore-acquisition technology. Recently, a 20-gauge (20G) antegrade-cutting-side-bevelled biopsy needle (ProCore®) was developed for EUS-TA, but data about its diagnostic performance and histological capability are scant., Objectives: We assessed the diagnostic performance and histologic retrieval rate of a new 20G antegrade-cutting-side-bevelled biopsy needle compared with a 22G reverse-side-bevelled needle for EUS sampling of solid pancreatic lesions., Patients and Methods: A retrospective analysis of 238 consecutively collected patients who underwent EUS-TA using a 20G or a 22G ProCore® needle, without rapid on-site evaluation (ROSE), was conducted at two centres.Sensitivity, specificity, positive predictive value and negative predictive value were calculated. Histologic tissue retrieval was evaluated applying a scoring system for each case., Results: Sensitivity and specificity were estimated as 98.4-100% in the 20G-, and 94.9-100% in the 22G-needle groups, respectively ( p > 0.99). The 20G procured more histologic-grade tissues (92.6% vs 49.5%, p < 0.0001) achieved by a lower number of passes (2.64 vs 3.44, p < 0.0001) compared to the 22G., Conclusions: Both side-bevelled FNB needles achieved a high diagnostic sensitivity. The 20G-side-bevelled needle obtained a significantly higher microcore retrieval rate.
- Published
- 2019
- Full Text
- View/download PDF
16. The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
- Author
-
Marchiò C, Dell'Orto P, Annaratone L, Geyer FC, Venesio T, Berrino E, Verdun di Cantogno L, Garofoli A, Rangel N, Casorzo L, dell'Aglio C, Gugliotta P, Trisolini E, Beano A, Pietribiasi F, Orlassino R, Cassoni P, Pich A, Montemurro F, Mottolese M, Vincent-Salomon A, Penault-Llorca F, Medico E, Ng CKY, Viale G, and Sapino A
- Subjects
- Adult, Biomarkers, Tumor genetics, Female, Gene Expression Profiling, Humans, Middle Aged, Biomarkers, Tumor analysis, Breast Neoplasms genetics, Breast Neoplasms pathology, Carcinoma genetics, Carcinoma pathology, Receptor, ErbB-2 genetics
- Abstract
The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2013 guidelines for HER2 assessment have increased the number of HER2 equivocal breast carcinomas following in situ hybridization reflex testing, that is, HER2 "double equivocal" (equivocal protein expression and equivocal gene copy number). Forty-five double-equivocal carcinomas were subjected to Prosigna analysis. Twenty-seven cases were investigated for the expression of genes found to be differentially expressed between estrogen receptor (ER)-positive/HER2-positive (N=22) and ER-positive/HER2-negative (N=22) control cases. Twenty-nine of the 45 cases were also analyzed by targeted sequencing using a panel of 14 genes. We then explored the pathologic complete response rates in an independent series of double-equivocal carcinoma patients treated with trastuzumab-containing chemotherapy. All cases were ER-positive, with a mean Ki67 of 28%. Double-equivocal carcinomas were predominantly luminal B (76%); 9 cases (20%) were luminal A, and 2 cases (4%) HER2-enriched. The majority (73%) showed a high risk of recurrence by Prosigna, even when the carcinomas were small (<2 cm), node-negative/micrometastatic, and/or grade 2. Double-equivocal carcinomas showed TP53 (6/29, 20%), PIK3CA (3/29, 10%), HER2 (1/29, 3%), and MAP2K4 (1/29, 3%) mutations. Compared with grade-matched ER-positive/HER2-negative breast carcinomas from METABRIC, double-equivocal carcinomas harbored more frequently TP53 mutations and less frequently PIK3CA mutations (P<0.05). No significant differences were observed with grade-matched ER-positive/HER2-positive carcinomas. Lower pathologic complete response rates were observed in double-equivocal compared with HER2-positive patients (10% vs. 60%, P=0.009). Double-equivocal carcinomas are preferentially luminal B and show a high risk of recurrence. A subset of these tumors can be labeled as HER2-enriched by transcriptomic analysis. HER2 mutations can be identified in HER2 double-equivocal cases.
- Published
- 2018
- Full Text
- View/download PDF
17. FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.
- Author
-
Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M, Trisolini E, Meunier S, Schmitt Y, Idbaih A, Hoang-Xuan K, Delattre JY, Mokhtari K, Di Stefano AL, and Sanson M
- Subjects
- Adolescent, Adult, Aged, Brain Neoplasms epidemiology, DNA Methylation, DNA Modification Methylases genetics, DNA Modification Methylases metabolism, DNA Mutational Analysis, DNA Repair Enzymes genetics, DNA Repair Enzymes metabolism, Female, Gene Expression Regulation, Neoplastic genetics, Glioma epidemiology, Humans, Isocitrate Dehydrogenase metabolism, Ki-67 Antigen metabolism, Male, Middle Aged, Retrospective Studies, Statistics, Nonparametric, Tumor Suppressor Proteins genetics, Tumor Suppressor Proteins metabolism, Young Adult, Brain Neoplasms genetics, Glioma genetics, Mesencephalon pathology, Mutation genetics, Receptor, Fibroblast Growth Factor, Type 1 genetics
- Abstract
Objective: To characterize the prevalence and prognostic significance of major driver molecular alterations in adult midline diffuse gliomas (MLG)., Methods: Adults with histologically proven MLG diagnosed between 1996 and 2017 were identified from our tumor bank, systematically reviewed, and reclassified according to WHO 2016. Targeted sequencing was performed, including determination of H3F3A , HIST1H3B , TERTp , IDH1/2 , FGFR1 , p16/CDKN2A , and EGFR status., Results: A total of 116 adult patients (M/F 71/45, median age 46.5 years) with MLG (17 cerebellar, 8 spinal, 30 brainstem, 57 thalamic, and 4 diencephalic nonthalamic) were identified. Most patients had high-grade disease at presentation (grade II: 11%, grade III: 15%, grade IV: 75%). Median overall survival was 17.3 months (14.5-23.8 months). Main molecular alterations observed were TERT promoter, H3F3A , and hotspot FGFR1 (N546 and K656) mutations, in 37%, 34%, and 18% of patients, respectively. IDH1 mutations only affected brainstem gliomas (6/24 vs 0/78; p = 7.5 × 10
-5 ), were mostly non-R132H (contrasting with hemispheric gliomas, p = 0.0001), and were associated with longer survival (54 vs 12 months). TERT promoter mutation (9.1 vs 24.2 months), CDKN2A deletion (9.9 vs 23.8 months), and EGFR amplification (4.3 vs 23.8 months) were associated with shorter survival. Of interest, in contrast with pediatric MLG, H3K27M mutations were not associated with worse prognosis (23 vs 15 months)., Conclusions: Patients with adult MLG present with unique clinical and molecular characteristics, differing from their pediatric counterparts. The identification of potentially actionable FGFR1 mutations in a subset of adult MLG highlights the importance of comprehensive genomic analysis in this rare affection., (© 2018 American Academy of Neurology.)- Published
- 2018
- Full Text
- View/download PDF
18. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma.
- Author
-
Rrapaj E, Trisolini E, Bertero L, Salvo M, Indellicato R, Andorno S, Garcia-Manteiga JM, Rena O, and Boldorini RL
- Subjects
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, HMGB1 Protein analysis, Humans, Kaplan-Meier Estimate, Lung Neoplasms mortality, Male, Mesothelioma mortality, Mesothelioma, Malignant, Middle Aged, Pleural Neoplasms mortality, Prognosis, Biomarkers, Tumor analysis, HMGB1 Protein biosynthesis, Lung Neoplasms pathology, Mesothelioma pathology, Pleural Neoplasms pathology
- Abstract
Aims: High mobility group box 1 (HMGB1) is a chromatin structural protein, expressed ubiquitously in the nuclei of mammalian cells. When transported extracellularly, it acts as a tumour suppressor and oncogenic protein. In malignant pleural mesothelioma (MPM), high serum levels of HMGB1 have been related to a poor prognosis. Conversely, the significance of HMGB1 expression in MPM tissues is still unclear., Methods and Results: Biopsy samples from 170 patients with MPM were assessed by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) to evaluate HMGB1 protein and gene expression. The expression level of HMGB1 protein was scored using a semiquantitative system that sums the intensity (0-3) and the percentage (from 0 to 4) of positively stained cells in nuclei, cytoplasm and in both. The final score was considered as high (>3) or low (<3) expression. Gene expression levels were calculated using the ΔΔC
t method. High expression levels of HMGB1 as total (P = 0.0011) and cytoplasmic score (P = 0.0462) were related to a worse disease-specific survival (DSS) in the entire cohort and in the clinicopathological subgroups. No significant correlation was found between HMGB1 gene expression and DSS., Conclusions: These findings indicate that HMGB1 may be a useful prognostic biomarker in MPM when detected by immunohistochemistry. Conversely, as it is also expressed in normal and reactive mesothelial cells, HMGB1 cannot be considered a diagnostic biomarker in histological samples of mesothelioma., (© 2018 John Wiley & Sons Ltd.)- Published
- 2018
- Full Text
- View/download PDF
19. β-HPV Infection Correlates with Early Stages of Carcinogenesis in Skin Tumors and Patient-Derived Xenografts from a Kidney Transplant Recipient Cohort.
- Author
-
Borgogna C, Olivero C, Lanfredini S, Calati F, De Andrea M, Zavattaro E, Savoia P, Trisolini E, Boldorini R, Patel GK, and Gariglio M
- Abstract
Many malignancies that occur in high excess in kidney transplant recipients (KTRs) are due to viruses that thrive in the setting of immunosuppression. Keratinocyte carcinoma (KC), the most frequently occurring cancer type in KTR, has been associated with skin infection by human papillomavirus (HPV) from the beta genus. In this report, we extend our previous investigation aimed at identifying the presence of active β-HPV infection in skin tumors from KTRs through detection of viral protein expression. Using a combination of antibodies raised against the E4 and L1 proteins of the β-genotypes, we were able to visualize infection in five tumors [one keratoacanthoma (KA), three actinic keratoses (AKs), and one seborrheic keratoses (SKs)] that were all removed from two patients who had been both transplanted twice, had developed multiple KCs, and presented with a long history of immunosuppression (>30 years). These infected tissues displayed intraepidermal hyperplasia and increased expression of the ΔNp63 protein, which extended into the upper epithelial layers. In addition, using a xenograft model system in nude mice displaying a humanized stromal bed in the site of grafting, we successfully engrafted three AKs, two of which were derived from the aforementioned KTRs and displayed β-HPV infection in the original tumor. Of note, one AK-derived xenograft, along with its ensuing lymph node metastasis, was diagnosed as squamous cell carcinoma (SCC). In the latter, both β-HPV infection and ΔNp63 expression were no longer detectable. Although the overall success rate of engrafting was very low, the results of this study show for the first time that β-HPV
+ and ΔNp63+ intraepidermal hyperplasia can indeed progress to an aggressive SCC able to metastasize. Consistent with a series of reports attributing a causative role of β-HPV at early stages of skin carcinogenesis through ΔNp63 induction and increased keratinocytes stemness, here we provide in vivo evidence that these events are also occurring in the affected skin of KTRs. Due to these β-HPV-driven molecular pathways, the nascent tumor cell is able to acquire a high enough number of carcinogenic insults that its proliferation and survival will eventually become independent of viral gene expression.- Published
- 2018
- Full Text
- View/download PDF
20. Oxidative and ER stress-dependent ASK1 activation in steatotic hepatocytes and Kupffer cells sensitizes mice fatty liver to ischemia/reperfusion injury.
- Author
-
Imarisio C, Alchera E, Bangalore Revanna C, Valente G, Follenzi A, Trisolini E, Boldorini R, and Carini R
- Subjects
- Animals, Diet, High-Fat adverse effects, Endoplasmic Reticulum Stress genetics, Fatty Liver enzymology, Fatty Liver etiology, Fatty Liver pathology, Gene Expression Regulation, Hepatocytes drug effects, Hepatocytes pathology, Kupffer Cells drug effects, Kupffer Cells pathology, Liver pathology, Liver surgery, MAP Kinase Kinase 4 genetics, MAP Kinase Kinase 4 metabolism, MAP Kinase Kinase Kinase 5 metabolism, Male, Mice, Mice, Inbred C57BL, Oxidative Stress, Palmitic Acid pharmacology, Primary Cell Culture, Reperfusion Injury enzymology, Reperfusion Injury pathology, Signal Transduction, p38 Mitogen-Activated Protein Kinases genetics, p38 Mitogen-Activated Protein Kinases metabolism, Fatty Liver genetics, Hepatocytes enzymology, Kupffer Cells enzymology, Liver enzymology, MAP Kinase Kinase Kinase 5 genetics, Reperfusion Injury genetics
- Abstract
Steatosis intensifies hepatic ischemia/reperfusion (I/R) injury increasing hepatocyte damage and hepatic inflammation. This study evaluates if this process is associated to a differential response of steatotic hepatocytes (HP) and Kupffer cells (KC) to I/R injury and investigates the molecular mechanisms involved. Control or steatotic (treated with 50 μmol palmitic acid, PA) mouse HP or KC were exposed to hypoxia/reoxygenation (H/R). C57BL/6 mice fed 9 week with control or High Fat diet underwent to partial hepatic IR. PA increased H/R damage of HP and further activated the ASK1-JNK axis stimulated by ER stress during H/R. PA also induced the production of oxidant species (OS), and OS prevention nullified the capacity of PA to increase H/R damage and ASK1/JNK stimulation. ASK1 inhibition prevented JNK activation and entirely protected HP damage. In KC, PA directly activated ER stress, ASK1 and p38 MAPK and increased H/R damage. However, in contrast to HP, ASK1 inhibition further increased H/R damage by preventing p38 MAPK activation. In mice liver, steatosis induced the expression of activated ASK1 in only KC, whereas I/R exposure of steatotic liver activated ASK1 expression also in HP. "In vivo", ASK1 inhibition prevented ASK1, JNK and p38 MAPK activation and protected I/R damage and expression of inflammatory markers., Conclusions: Lipids-induced ASK1 stimulation differentially affects HP and KC by promoting cytotoxic or protective signals. ASK1 increases H/R damage of HP by stimulating JNK and protects KC activating p38MAPK. These data support the potentiality of the therapeutic employment of ASK1 inhibitors that can antagonize the damaging effects of I/R upon fatty liver surgery by the contextual reduction of HP death and of KC-mediated reactions., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
21. Frequent detection of Merkel cell polyomavirus DNA in tissues from 10 consecutive autopsies.
- Author
-
Mancuso G, Antona J, Sirini C, Salvo M, Giacometti L, Olivero C, Trisolini E, Indellicato R, and Boldorini R
- Subjects
- Humans, Merkel cell polyomavirus genetics, Real-Time Polymerase Chain Reaction, Viral Load, Autopsy, DNA, Viral isolation & purification, Merkel cell polyomavirus isolation & purification, Polyomavirus Infections virology, Tumor Virus Infections virology
- Abstract
Merkel cell polyomavirus (MCPyV) has been identified in samples of Merkel cell carcinoma (MCC), an aggressive skin cancer. Seroepidemiologic studies indicated a high frequency of MCPyV infection in humans, suggesting respiratory and faecal-oral routes, or transmission by skin contact. Since MCC is more frequent in immunocompromised patients, a reactivation of MCPyV latently infecting target cells has been proposed. However, neither definite ways of transmission nor specific target organs have been identified with certainty. Ten autopsies with an extensive organ sampling for a total of 121 specimens (tissue and blood samples) were collected. All tissue specimens were fixed in formalin and embedded in paraffin. Real-time PCR was performed to quantify the copy number of the large T antigen (LT) gene and the capsid VP1 gene of MCPyV. MCPyV LT and/or VP genes were detected in all of the collected specimens. A high prevalence of MCPyV was found in the blood (six cases) and lung (five cases); the brain was positive in three cases. The highest viral copy number was detected in blood from two autopsies (21 610 570.09 copies per 105 cells and 380 413.25 copies per 105 cells), whereas the viral copy number in the other organs was low. Our data confirm the high frequency of MCPyV infection in the general population, which seems to indicate that the respiratory tract is a possible route for viral transmission and viral persistence in the brain. The frequent detection of MCPyV DNA in blood suggests that circulating leukocytes could be one of the reservoirs of MCPyV, whereas the high viral copy number also seems to indicate the possibility of viral reactivation in immunocompetent adults.
- Published
- 2017
- Full Text
- View/download PDF
22. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy.
- Author
-
Trisolini E, Armellini E, Paganotti A, Veggiani C, Bozzola C, Frattini M, Pizio C, Mancuso G, Andorno S, and Boldorini R
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Pancreatic Ductal diagnosis, Carcinoma, Pancreatic Ductal genetics, DNA Mutational Analysis methods, Female, Humans, Male, Middle Aged, Pancreatic Diseases genetics, Pancreatic Neoplasms genetics, Pancreatic Neoplasms pathology, Endoscopic Ultrasound-Guided Fine Needle Aspiration methods, Mutation genetics, Pancreatic Diseases diagnosis, Pancreatic Neoplasms diagnosis, Proto-Oncogene Proteins p21(ras) genetics
- Abstract
Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the procedure of choice for the cytologic diagnosis of pancreatic masses. The specificity of EUS-FNA approaches 100%, but the sensitivity is still low, and the high rate of indeterminate (atypical and suspicious) and false-negative results needs improvement. KRAS gene is frequently mutated in pancreatic ductal adenocarcinoma (PDAC) (up to 90%), and mutation analysis of KRAS has been proposed as diagnostic biomarker of PDAC. In most laboratories, KRAS mutation testing is performed by Sanger sequencing or real time-quantitative polymerase chain reaction (RT-qPCR), but these methods may give false-negative results in routine samples, mainly due to low cellularity. In order to increase the sensitivity of EUS-FNA, we propose a sequential approach for detecting KRAS mutations using mutant enriched-PCR (ME-PCR, sensitivity up to 0.1%) in cytologically indeterminate and negative samples tested wild-type by RT-qPCR. EUS-FNA specimens from 107 patients with pancreatic masses (51 males, 56 females, mean age 67 years) were cytologically examined. According to the Papanicolaou Society of Cytopathology guidelines, 50 cases (47%) were classified malignant, 15 (14%) suspicious, 13 (12%) atypical and 10 (9%) negative for malignancy; 18 cases (17%) were non-diagnostic. The overall specificity and sensitivity of cytological examination were 100% and 61%, respectively, when only negative and positive cases were considered; when atypical and suspicious were added to positive cases, the sensitivity increased to 95.1% and the specificity decreased to 85.7%. In all the cases, DNA was extracted from the cell-block and KRAS mutations were investigated by RT-qPCR, followed by ME-PCR in non-amplifiable and negative cases. The overall sensitivity and specificity of KRAS mutation testing alone were 79.3% and 100%; when KRAS mutation testing was performed in indeterminate and negative cytology, the sensitivity increased to 90% with specificity to 100%. Our data indicate that conventional cytology from EUS-FNA samples is highly specific for the diagnosis of pancreatic cancer. Indeterminate and negative cases need to be screened for KRAS mutations; this two-step approach may greatly improve the diagnostic accuracy of this method., (Copyright © 2017 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
23. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.
- Author
-
Petti C, Picco G, Martelli ML, Trisolini E, Bucci E, Perera T, Isella C, and Medico E
- Subjects
- Animals, Cell Line, Tumor, Cell Survival, DNA, Complementary metabolism, ErbB Receptors metabolism, Female, Gene Library, Humans, Indoles chemistry, Mice, Mice, Nude, Neoplasm Transplantation, Phenotype, Protein Kinase Inhibitors chemistry, Proto-Oncogene Proteins B-raf metabolism, Receptor Protein-Tyrosine Kinases metabolism, Sulfones chemistry, Time Factors, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-met metabolism, Stomach Neoplasms metabolism, raf Kinases metabolism
- Abstract
Constitutively active receptor tyrosine kinases (RTKs) are known oncogenic drivers and provide valuable therapeutic targets in many cancer types. However, clinical efficacy of RTK inhibitors is limited by intrinsic and acquired resistance. To identify genes conferring resistance to inhibition of the MET RTK, we conducted a forward genetics screen in the GTL-16 gastric cancer cell line, carrying MET amplification and exquisitely sensitive to MET inhibition. Cells were transduced with three different retroviral cDNA expression libraries and selected for growth in the presence of the MET inhibitor PHA-665752. Selected cells displayed robust and reproducible enrichment of library-derived cDNAs encoding truncated forms of RAF1 and BRAF proteins, whose silencing reversed the resistant phenotype. Transduction of naïve GTL-16 cells with truncated, but not full length, RAF1 and BRAF conferred in vitro and in vivo resistance to MET inhibitors, which could be reversed by MEK inhibition. Induction of resistance by truncated RAFs was confirmed in other MET-addicted cell lines, and further extended to EGFR-addicted cells. These data show that truncated RAF1 and BRAF proteins, recently described as products of genomic rearrangements in gastric cancer and other malignancies, have the ability to render neoplastic cells resistant to RTK-targeted therapy.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.